{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T21:03:24Z","timestamp":1772744604596,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,5]]},"DOI":"10.7759\/cureus.104726","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T20:18:21Z","timestamp":1772741901000},"source":"Crossref","is-referenced-by-count":0,"title":["Opsoclonus-Myoclonus-Ataxia Syndrome Related to Pembrolizumab Treatment for Invasive Ductal Carcinoma: A Case Report"],"prefix":"10.7759","author":[{"given":"Ananta","family":"Sriram","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Polhemus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilson","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divya","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jafar","family":"Kafaie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00369-1","article-title":"Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes","volume":"23","author":"Farina A","year":"2024","unstructured":"Farina A, Villagr\u00e1n-Garc\u00eda M, Vogrig A, et al.. Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes. Lancet Neurol. 2024, 23:81-94. 10.1016\/S1474-4422(23)00369-1","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0194-4","article-title":"Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors","volume":"16","author":"Graus F","year":"2019","unstructured":"Graus F, Dalmau J. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2019, 16:535-48. 10.1038\/s41571-019-0194-4","journal-title":"Nat Rev Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-02902-0","article-title":"Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired","volume":"23","author":"Marei HE","year":"2023","unstructured":"Marei HE, Hasan A, Pozzoli G, Cenciarelli C. Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. Cancer Cell Int. 2023, 23:64. 10.1186\/s12935-023-02902-0","journal-title":"Cancer Cell Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0359","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature","volume":"24","author":"Reynolds KL","year":"2019","unstructured":"Reynolds KL, Guidon AC. Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature. Oncologist. 2019, 24:435-43. 10.1634\/theoncologist.2018-0359","journal-title":"Oncologist"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418799864","article-title":"Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system","volume":"11","author":"Dalakas MC","year":"2018","unstructured":"Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system. Ther Adv Neurol Disord. 2018, 11:10.1177\/1756286418799864","journal-title":"Ther Adv Neurol Disord"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21165774","article-title":"Immune-driven pathogenesis of neurotoxicity after exposure of cancer patients to immune checkpoint inhibitors","volume":"21","author":"Vilari\u00f1o N","year":"2020","unstructured":"Vilari\u00f1o N, Bruna J, Kalofonou F, Anastopoulou GG, Argyriou AA. Immune-driven pathogenesis of neurotoxicity after exposure of cancer patients to immune checkpoint inhibitors. Int J Mol Sci. 2020, 21:5774. 10.3390\/ijms21165774","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0821-8","article-title":"Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study","volume":"7","author":"Manson G","year":"2019","unstructured":"Manson G, Maria AT, Poizeau F, et al.. Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study. J Immunother Cancer. 2019, 7:337. 10.1186\/s40425-019-0821-8","journal-title":"J Immunother Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-9138-7","article-title":"Update on opsoclonus-myoclonus syndrome in adults","volume":"266","author":"Oh SY","year":"2019","unstructured":"Oh SY, Kim JS, Dieterich M. Update on opsoclonus-myoclonus syndrome in adults. J Neurol. 2019, 266:1541-8. 10.1007\/s00415-018-9138-7","journal-title":"J Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8111777","article-title":"Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy\u2014review of the literature and future outlook","volume":"8","author":"M\u00f6hn N","year":"2019","unstructured":"M\u00f6hn N, Beutel G, Gutzmer R, Ivanyi P, Satzger I, Skripuletz T. Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy\u2014review of the literature and future outlook. J Clin Med. 2019, 8:1777. 10.3390\/jcm8111777","journal-title":"J Clin Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.14003","article-title":"Autoimmune movement disorders complicating treatment with immune checkpoint inhibitors","volume":"11","author":"Dinoto A","year":"2024","unstructured":"Dinoto A, Trentinaglia M, Carta S, et al.. Autoimmune movement disorders complicating treatment with immune checkpoint inhibitors. Mov Disord Clin Pract. 2024, 11:543-9. 10.1002\/mdc3.14003","journal-title":"Mov Disord Clin Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/EB.S277760","article-title":"Neuro-ophthalmic complications of immune checkpoint inhibitors: a systematic review","volume":"12","author":"Yu CW","year":"2020","unstructured":"Yu CW, Yau M, Mezey N, Joarder I, Micieli JA. Neuro-ophthalmic complications of immune checkpoint inhibitors: a systematic review. Eye Brain. 2020, 12:139-67. 10.2147\/EB.S277760","journal-title":"Eye Brain"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.1912","article-title":"Neurological complications associated with anti-programmed death 1 (PD-1) antibodies","volume":"74","author":"Kao JC","year":"2017","unstructured":"Kao JC, Liao B, Markovic SN, et al.. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol. 2017, 74:1216-22. 10.1001\/jamaneurol.2017.1912","journal-title":"JAMA Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13375","article-title":"Neurological immune-related adverse events associated with immune checkpoint inhibitors: a review of the literature","volume":"16","author":"Fan S","year":"2020","unstructured":"Fan S, Ren H, Zhao L, Yin J, Feng G, Wang J, Guan H. Neurological immune-related adverse events associated with immune checkpoint inhibitors: a review of the literature. Asia Pac J Clin Oncol. 2020, 16:291-8. 10.1111\/ajco.13375","journal-title":"Asia Pac J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X19666201230151224","article-title":"Immune checkpoint inhibitors and neurotoxicity","volume":"19","author":"Zhao Z","year":"2021","unstructured":"Zhao Z, Zhang C, Zhou L, Dong P, Shi L. Immune checkpoint inhibitors and neurotoxicity. Curr Neuropharmacol. 2021, 19:1246-63. 10.2174\/1570159X19666201230151224","journal-title":"Curr Neuropharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2017.144","article-title":"Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives","volume":"13","author":"Yshii LM","year":"2017","unstructured":"Yshii LM, Hohlfeld R, Liblau RS. Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nat Rev Neurol. 2017, 13:755-63. 10.1038\/nrneurol.2017.144","journal-title":"Nat Rev Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-021-03695-w","article-title":"Neurotoxicities associated with immune checkpoint inhibitor therapy","volume":"152","author":"Duong SL","year":"2021","unstructured":"Duong SL, Barbiero FJ, Nowak RJ, Baehring JM. Neurotoxicities associated with immune checkpoint inhibitor therapy. J Neurooncol. 2021, 152:265-77. 10.1007\/s11060-021-03695-w","journal-title":"J Neurooncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/466144-opsoclonus-myoclonus-ataxia-syndrome-related-to-pembrolizumab-treatment-for-invasive-ductal-carcinoma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T20:18:22Z","timestamp":1772741902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/466144-opsoclonus-myoclonus-ataxia-syndrome-related-to-pembrolizumab-treatment-for-invasive-ductal-carcinoma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.104726","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,5]]}}}